Mukae H, Hirota M, Morikawa N, Oda H, Sakito O, Shikuwa T, Senju R, Fukushima K, Hiratani K, Kadota J
Nihon Kyobu Shikkan Gakkai Zasshi. 1989 Aug;27(8):881-6.
Serum levels of sialylated Lewisx (SLEX) and sialylated SSEA-1 (S-Xi) in 136 cases of diagnosed lung cancer (63 adenocarcinoma, 45 squamous cell carcinoma, 20 small cell carcinoma and 8 large cell carcinoma) and 111 cases of benign pulmonary disease were measured. The positive rate of these markers in the primary lung cancer group was significantly higher than those in benign pulmonary diseases. The positive rates of serum SLEX and S-Xi in all lung cancer cases were 27.2% and 27.9%, respectively. The antigen levels in the sera were higher in adenocarcinoma as compared to other histologic types, and increased as the stage advanced. It was concluded that SLEX and S-Xi are very useful markers of lung cancer for diagnosis and monitoring the clinical status.
检测了136例确诊肺癌患者(63例腺癌、45例鳞状细胞癌、20例小细胞癌和8例大细胞癌)及111例良性肺病患者血清中唾液酸化刘易斯x(SLEX)和唾液酸化阶段特异性胚胎抗原-1(S-Xi)的水平。这些标志物在原发性肺癌组中的阳性率显著高于良性肺病组。所有肺癌病例中血清SLEX和S-Xi的阳性率分别为27.2%和27.9%。腺癌患者血清中的抗原水平高于其他组织学类型的患者,且随分期进展而升高。得出结论,SLEX和S-Xi是用于肺癌诊断和监测临床状态的非常有用的标志物。